SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 17, 2003

 

ARQULE, INC.
(Exact Name of Issuer as Specified in Charter)

 

Delaware		000-21429		04-3221586
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

19 Presidential Way Woburn, MA

(Address of principal executive offices)

01801

(Zip code)

(781) 994-0300

(Registrant’s telephone number, including area code)

---

 

Item 5.    Other Events and Regulation FD Disclosure

On July 17, 2003, ArQule, Inc. announced that it signed a definitive agreement to acquire Cyclis Pharmaceuticals, Inc. The press release announcing the execution of the agreement is filed as Exhibit 99.1 hereto and incorporated herein by reference.

 
Item 7.    Financial Statements and Exhibits

(c)  Exhibits

99.1 Text of Press Release, dated July 17, 2003.

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				ARQULE, INC. (Registrant)
				/s/ Stephen A. Hill Stephen A. Hill President and Chief Executive Officer
Date:		July 18, 2003